Mass spectrometry

Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets

Retrieved on: 
Tuesday, March 5, 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics that mimic T-cell receptors (TCR-mimetics), today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia.

Key Points: 
  • The oral presentation will provide an overview of the preclinical characteristics of CBX-250, which targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex.
  • The complex is abundantly expressed on leukemic cells, but not on normal cells, allowing CBX-250 to target cancer cells efficiently while sparing normal myeloid cells.
  • “Nominating CBX-250 as a development candidate validates our initial scientific hypothesis, and it brings us a step closer to entering the clinic and ultimately helping to cure cancer,” said Briggs Morrison, Chief Executive Officer of Crossbow.
  • Working with MD Anderson’s ORBIT platform, a core component of the institution’s Therapeutics Discovery division , Dr. Molldrem led the development of a TCR-mimetic binder to the CG1 pHLA complex, which Crossbow licensed for the development of off-the-shelf cancer immunotherapies.

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, February 28, 2024

AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.

Key Points: 
  • AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.
  • Net cash used in operations full-year 2023 was $82.0 million, consistent with previous guidance.
  • (This amount is not included in the above cash and cash equivalents at December 31, 2023.)
  • Recent corporate highlights include the following:
    In January 2024, we completed a dividend distribution of common stock warrants to shareholders.

Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing™ on Platinum® at US HUPO Conference

Retrieved on: 
Thursday, March 7, 2024

WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.

Key Points: 
  • WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.
  • Additionally, researchers will present data from Platinum and highlight how protein sequencing on the benchtop instrument is providing deeper insights into proteins through streamlined workflows.
  • WHY: Quantum-Si brings the groundbreaking power of single-molecule proteomics with the first-to-market Next-Generation Protein Sequencer™, the Platinum instrument, to every lab, everywhere.
  • WHERE: The 2024 US HUPO Conference is being held at the Hyatt Regency Portland, 375 NE Holladay St, Portland, OR 97232

Security Screening Market worth $13.2 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, March 4, 2024

People screening has been one of the key uses of security screening systems at different places, such as airports, shopping malls, hotels and resorts, and corporate offices.

Key Points: 
  • People screening has been one of the key uses of security screening systems at different places, such as airports, shopping malls, hotels and resorts, and corporate offices.
  • The security screening industry in North America is witnessing significant developments amidst rising concerns over illicit fentanyl smuggling and other security threats.
  • Furthermore, the integration of biometric security solutions plays a pivotal role in augmenting the effectiveness of security screening processes.
  • S.p.A. (Italy), Aware Inc. (US), Scanna (UK), and Precise Biometrics (Sweden) are the major players in security screening companies .

Security Screening Market worth $13.2 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, March 4, 2024

People screening has been one of the key uses of security screening systems at different places, such as airports, shopping malls, hotels and resorts, and corporate offices.

Key Points: 
  • People screening has been one of the key uses of security screening systems at different places, such as airports, shopping malls, hotels and resorts, and corporate offices.
  • The security screening industry in North America is witnessing significant developments amidst rising concerns over illicit fentanyl smuggling and other security threats.
  • Furthermore, the integration of biometric security solutions plays a pivotal role in augmenting the effectiveness of security screening processes.
  • S.p.A. (Italy), Aware Inc. (US), Scanna (UK), and Precise Biometrics (Sweden) are the major players in security screening companies .

Groundbreaking New Blood Test Offers Early Pancreatic Cancer Diagnosis Study Says

Retrieved on: 
Thursday, February 29, 2024

LONG BEACH, Calif., Feb. 29, 2024 /PRNewswire/ -- As reported in today's issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the first time applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism and that these changes can be measured with a simple blood test.

Key Points: 
  • "Pancreatic cancer is the third leading cause of death from cancer largely because it is rarely caught early," said Dr. Robert Nagourney, senior author.
  • Using Mass Spectrometry to measure minute concentrations of bio-chemicals in the plasma, the technique identified pancreatic cancer in the blood with near perfect accuracy.
  • The results provide a "cancer signature" that distinguishes patients with pancreatic cancer from normal individuals and can distinguish pancreatic cancer from other forms of cancer, like breast and ovarian.
  • Following Genomics, the study of DNA and Proteomics, the study of cell proteins, metabolomics, is the new "omic" to watch.

Journal of Pharmaceutical Analysis Articles Provide Novel Insights into Previously Unknown Disease Mechanisms

Retrieved on: 
Tuesday, February 27, 2024

XI'AN, China, Feb. 27, 2024 /PRNewswire/ -- DCM is the leading cause of heart failure in patients with chronic diabetes, with unclear mechanisms and limited treatments. Another mystery is the regulation of cytochrome P450 enzymes (CYPs) in the central nervous system. Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown. In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.

Key Points: 
  • Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown.
  • In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.
  • Their findings, available online on 17 August 2023, were published in Volume 13, Issue 12 of the journal in December 2023.
  • Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease

Bioburden Testing Market worth $2.59 billion by 2031 Owing To Increasing Demand for Quality Assurance and Safety Measures - Exclusive Report by Coherent Market Insights

Retrieved on: 
Thursday, February 15, 2024

The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.

Key Points: 
  • The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.
  • Their strong market presence and diverse product portfolio contribute to the overall growth of the bioburden testing market.
  • In summary, the bioburden testing market presents significant opportunities, with the consumables segment and aerobic count testing expected to dominate.
  • These market takeaways highlight the key factors influencing the bioburden testing market's growth and offer insights into its future direction.

Bioburden Testing Market worth $2.59 billion by 2031 Owing To Increasing Demand for Quality Assurance and Safety Measures - Exclusive Report by Coherent Market Insights

Retrieved on: 
Thursday, February 15, 2024

The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.

Key Points: 
  • The demand for rapid microbiological testing methods is increasing as they offer numerous advantages, including reduced testing time and improved efficiency.
  • Their strong market presence and diverse product portfolio contribute to the overall growth of the bioburden testing market.
  • In summary, the bioburden testing market presents significant opportunities, with the consumables segment and aerobic count testing expected to dominate.
  • These market takeaways highlight the key factors influencing the bioburden testing market's growth and offer insights into its future direction.

MATTERWORKS ANNOUNCES BOARD UPDATES

Retrieved on: 
Monday, February 12, 2024

SOMERVILLE, Mass., Feb. 12, 2024 /PRNewswire/ -- Matterworks, Inc., developers of a foundational AI platform for modeling biology to accelerate discovery and development in the life sciences, today announces additions to its Board of Directors.

Key Points: 
  • SOMERVILLE, Mass., Feb. 12, 2024 /PRNewswire/ -- Matterworks, Inc., developers of a foundational AI platform for modeling biology to accelerate discovery and development in the life sciences, today announces additions to its Board of Directors.
  • Matterworks is pleased to announce the appointments of Michael Lavin, a Managing Partner at Germin8 Ventures and Dr. Shubhra Jain, Head of Health-Tech Venture Investments at Tarsadia, as Board Members.
  • Germin8 sought to find innovators who shared our thesis at the intersection of biotech workflows and generative AI, and Matterworks was inspirational and executing on every level.
  • Matterworks is uniquely positioned to leverage the latest advancements in AI to empower our scientific community and further our understanding of biology.